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bstract
ackground: Residual platelet reactivity (RPR) on antiplatelet therapy in ischemic heart disease patients is associated with adverse events.
linical, cellular and pharmacogenetic factors may account for the variable response to antiplatelet treatment.
bjective: We sought to explore the interplay of multiple pro-inflammatory and anti-inflammatory cytokines with platelet function in patients
ith acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) on dual antiplatelet therapy.
ethods: In 208 ACS patients undergoing PCI on dual antiplatelet therapy we measured platelet function by platelet aggregation with two
gonists [1 mM arachidonic acid (AA) and 10M ADP]. IL-1, IL-1ra, IL-4, IL-6, IL-8, IL-10, IL-12, IP-10, IFN-, MCP-1, MIP-1,
IP-1, TNF-, and VEGF levels were determined by using the Bio-Plex cytokine assay (Bio-Rad Laboratories Inc., Hercules, CA, USA).
e defined patients with RPR those with platelet aggregation by AA ≥20% and/or ADP (10mol) ≥70%.
esults: We documented a significant association between IP-10, IFN-, IL-4 and RPR by both AA- and ADP-induced platelet aggregation
fter adjustment for age, sex, cardiovascular risk factors, ejection fraction, BMI, vWF and CRP. Patients with pro-inflammatory cytokines
ot compensated by anti-inflammatory cytokines had higher risk of RPR by both AA and ADP (AA: OR = 3.85, 95% CI 1.52–9.74; ADP:
R = 2.49, 95% CI 1.33–4.68) with respect to patients with balanced anti-/pro-inflammatory cytokines. Patients with anti-inflammatory
esponse overwhelming pro-inflammatory response have lower risk of RPR (AA: OR = 0.55, 95% CI 0.28–1.06; ADP: OR = 0.47, 95% CI
.26–0.87).
onclusion: Our study provides new insights into the interplay of anti-/pro-inflammatory cytokines with platelet hyper-reactivity in high-risk
atients.
2008 Elsevier Ireland Ltd. All rights reserved.
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Good evidence exists indicating that inflammation plays
crucial role in the processes influencing the development
f ischemic events after percutaneous coronary intervention
PCI) [1]. Pro-inflammatory molecules are actively involved
n the activation and migration of leukocytes to sites of
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ascular injury and inflammation, and may contribute to the
elease by activated cells of prothrombotic factors, which in
urn may activate platelets and other cell types [2,3]. Platelets
epresent an important linkage between inflammation, throm-
osis, and atherogenesis, as they are able to interact with
eukocytes and endothelial cells with the participation of Von
illebrand factor (vWF) [4]. When activated, platelets coag-
regate with circulating leukocytes and after their adherence
o the vascular wall, platelets also provide a sticky surface to
ecruit leukocytes on the vessel wall [5].
Clinical studies documented that a residual platelet reac-
ivity (RPR) on antiplatelet therapy in patients with ischemic
eart disease is associated with adverse clinical events [6–10].
Clinical, cellular and pharmacogenetic factors may
ccount for the variable response to antiplatelet treatment
9,11–14].
The role of the inflammatory state in modulating the
ffect of antiplatelet therapy on platelet reactivity has been
uggested by clinical studies demonstrating the high preva-
ence of RPR in the acute phase of disease [15–16], and that
PR is independently associated with routinely inflammatory
arkers [erythrocyte sedimentation rate (ESR) and leuko-
yte number] in acute coronary syndrome (ACS) patients [9].
owever, the precise mechanisms by which the inflammatory
tate may influence platelet hyper-reactivity in high-risk car-
iac patients on dual antiplatelet therapy have not yet been
lucidated. In particular, no information is available about the
ynamic relationship between the various anti-inflammatory
nd pro-inflammatory molecules in relation to platelet acti-
ation.
Therefore, aim of the present study was to explore
he interplay of multiple pro-inflammatory and anti-
nflammatory cytokines with platelet function in patients with
CS undergoing PCI on dual antiplatelet therapy.
. Materials and methods
.1. Study population
In the framework of an ongoing project aimed to investi-
ate the prevalence and the clinical implications of a RPR in
atients with ACS undergoing PCI on dual antiplatelet ther-
py, we investigated 208 patients in relation to the presence
r the absence of RPR by AA defined as platelet aggregation
20% (92/208).
All patients undergoing primary PCI received a clopi-
ogrel loading dose (73 received 600 mg and 135 received
00 mg) followed by a daily dose of 75 mg. All patients
eceived unfractionated heparin 70 IU/kg during the proce-
ure and acetylsalicylic acid i.v. 500 mg followed by a daily
ose of 100–325 mg by oral route.Acute myocardial infarction (AMI) was diagnosed as an
ncrease in creatine kinase MB isoenzyme at least twice
he upper normal limits (3.6 ng/mL), and/or elevated car-
iac Troponin I (cTnI) (>0.15 ng/mL) levels with at least
i
(
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ne of the following: acute onset of prolonged (≥20 min)
ypical ischemic chest pain; ST-segment elevation of at least
mm in two or more contiguous electrocardiographic leads
r ST-depression of ≥0.5 mm, 0.08 s after the J point in
2 contiguous leads, or T waves inversion >1 mm in leads
ith predominant R waves. All patients underwent coronary
ngiography performed by the Judkins’ technique and PCI if
ndicated.
Unstable angina was defined as angina pain at rest ful-
lling Braunwald’s IIIb criteria with transient significant
schemic ST-segment or T-wave changes, or both, without
vidence of myocardial damage.
Patients were considered to have hypertension if they had
een diagnosed as hypertensives according to the guidelines
f European Society of Hypertension/European Society of
ardiology [17] or were taking antihypertensive drugs. Dys-
ipidemia was defined according to the third report of the
ational Cholesterol Education Program (NCEP III) [18] and
iabetes in agreement with the American Diabetes Associa-
ion [19].
The exclusion criteria included history of bleeding
iathesis, platelet count ≤100,000/mm3, hematocrit ≤30%,
reatinine ≥4.0 mg/dL, and glycoprotein (Gp) IIb/IIIa
nhibitors use.
Informed written consent was obtained from all patients
nd the study was approved by the local Ethical Review
oard. The investigation conforms with the principles out-
ined in the Declaration of Helsinki [20].
.2. Experimental procedure
Venous blood samples anticoagulated with 0.129 M
odium citrate (ratio 9:1) were taken from each patient 24 h
fter PCI. Whole venous blood was also collected in tubes
ithout anticoagulant.
Whole-blood specimens were centrifuged for 10 min at
50 × g to obtain platelet-rich plasma (PRP). As previously
escribed [9] PRP was stimulated with 2 and 10M ADP
Mascia Brunelli, Milan, Italy) and with 1 mM arachidonic
cid (AA) (Sigma–Aldrich, Milan, Italy) using a APACT 4
ggregometer (Helena Laboratories Italia s.p.a., Milan, Italy).
he coefficient of variation of AA-PA and ADP-PA were
.8% and 6.8%, respectively.
Citrated and serum samples were centrifuged at room tem-
erature (1500 × g) for 15 min. The supernatants were stored
n aliquots at −80 ◦C until assays.
Von Willebrand factor (vWF:Ag) was measured by an in-
ouse ELISA, based upon a commercial rabbit anti-human
WF polyclonal antibody (DAKO, Copenaghen, Denmark)
s first and second antibody.
Interleukin-1 (IL-1), interleukin 1 receptor antag-
nist (IL-1ra), interleukin-4 (IL-4), interleukin-6 (IL-6),
nterleukin-8 (IL-8), interleukin-10 (IL-10), interleukin-12
IL-12), interferon-inducible protein (IP-10), interferon-
(IFN-), monocyte chemoattractant protein-1 (MCP-
), macrophage inflammatory protein 1- (MIP-1),
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acrophage inflammatory protein 1- (MIP-1), tumor
ecrosis factor- (TNF-), and vascular endothelial growth
actor (VEGF) levels were determined by using the Bio-Plex
ytokine assay (Bio-Rad Laboratories Inc., Hercules, CA,
SA) according to manufacturer’s instructions.
C-reactive protein (CRP) was assessed by a high-
ensitivity assay on a BN II nephelometer (Dade Behring,
arburg, Germany) allowing detection of values as low as
.17 mg/L.
.3. Residual platelet reactivity
For selecting study population we defined patients with
PR those patients with platelet aggregation induced by AA
20%; in addition, we studied ADP-induced platelet aggre-
ation and we considered residual platelet reactivity to ADP.
ccording to literature [21,22] and studies from our group
9,10] for RPR by ADP we chose a cut-off value of 70%.
.4. Statistical analysis
Statistical analysis was performed with SPSS (Statistical
ackage for Social Sciences, Chicago, USA) software for
indows (Version 11.5). Values are presented as median and
ange.
As the parameters investigated had a non-Gaussian dis-
ribution, log-transformed values for cyto-chemokines, CRP
nd vWF were used in the analyses, and back transformed
or data presentation.
After logarithmic transformation the t-test for unpaired
ata was used for comparisons between single groups. Fur-
hermore, the evaluation of the relationship between pro-,
nti-inflammatory cytokines, CRP, vWF and platelet aggre-
ation by 1 mM AA or by 2 or 10M ADP was performed
y Pearson’s correlation test and p values were adjusted by
onferroni’s correction for multiple comparisons.
To perform the multivariate analysis, logistic regression
as used with RPR as the dependent variable and with the
arameters differently (p < 0.20) distributed between patients
ith and without RPR as the independent variables. Clinical
haracteristics (age, sex, cardiovascular risk factors) were
ncluded in the logistic regression analysis in a model in
hich vWF, CRP and cyto-chemokine levels were added as
ontinuous variable. Variables that resulted not to be asso-
iated with the outcome were removed from the final most
arsimonious regression model through a backward selec-
ion algorithm in a model in which all parameters were added
imultaneously.
High concentrations of pro-inflammatory markers were
efined as the highest tertile of the distribution of the
yto-chemokines. Low concentrations of anti-inflammatory
arkers were defined as the lowest tertile of the distribu-ion of these cyto-chemokines. The odds ratio for having
PR according to cyto-chemokine tertiles was estimated by
ultivariate logistic regression analysis, using RPR as depen-
ent variable, cyto-chemokines as independent variables, and
h
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ge, sex, BMI, traditional cardiovascular risk factors, ejection
raction CRP and vWF as covariates.
In order to evaluate the role of the balance between
nti-inflammatory and pro-inflammatory cytokines, we cat-
gorized patients into three groups: group 1 patients
ave a balanced anti-/pro-inflammatory cytokines, i.e. pro-
nflammatory and anti-inflammatory cytokines in the same
ertiles; group 2 patients have the pro-inflammatory cytokines
ot compensated by the anti-inflammatory cytokines, i.e.
ro-inflammatory cytokines in the third tertile and anti-
nflammatory cytokines in the first or second tertiles;
roup 3 patients in which the anti-inflammatory response
verwhelms the pro-inflammatory cytokines, i.e. pro-
nflammatory cytokine in the first or second tertiles and
nti-inflammatory cytokines in the third tertile.
All odds ratios (OR) are given with their 95% confidence
nterval. All probability values are two-tailed, with values of
ess than 0.05 considered statistically significant.
. Results
.1. Relationship between 1mM AA-induced platelet
ggregation and cyto-chemokine levels
The evaluation of the relationship between pro-, anti-
nflammatory cytokines and platelet aggregation by 1 mM
A, performed by Pearson’s correlation tests, showed that
P-10 and IL-6 serum levels, but not other pro-inflammatory
ytokines (IL-1, IL-8, IL-12, TNF-, MCP-1, MIP-1,
IP-1, IFN- and VEGF), were mildly, but signifi-
antly, related with platelet aggregation (IP-10: r = 0.30,
< 0.001; IL-6: r = 0.28, p < 0.05). Serum levels of anti-
nflammatory cytokines IL-4 and IL-10 were inversely related
ith platelet aggregation by AA (IL-4: r = −0.28, p < 0.05;
L-10: r = −0.20, p = 0.14).
.2. Relationship between CRP, vWF levels and 1mM
A-induced platelet aggregation
No significant association between CRP serum levels and
A-induced platelet aggregation was found.
A significant association between vWF levels and
A-induced platelet aggregation (r = 0.30, p < 0.001) was
ocumented.
.3. Residual platelet reactivity (RPR) by AA and
yto-chemokine, CRP and vWF levels
Age, diabetes and vWF levels were significantly associ-
ted with RPR by AA (Table 1).
IL-6, IP-10, IFN- and vWF levels were significantly
igher in patients with RPR than in patients without RPR
Table 1). IL-4 and IL-10 levels were significantly lower in
PR patients than in patients without RPR detected by AA
Table 1). No significant difference in CRP levels between
258 A.M. Gori et al. / Atherosclerosis 202 (2009) 255–262
Table 1
Clinical and laboratory characteristics according to the presence or the absence of residual platelet reactivity by AA-PA (AA-platelet aggregation ≥20%)
With RPR (n = 92) Without RPR (n = 116) p
Age 70.6 (68.2–72.1) 64.9 (65.1–68.5) 0.001
Sex (M/F) 62/30 90/26 0.182
Smoking habit, n (%) 38 (41.3) 52 (44.6) 0.610
Hypertension, n (%) 52 (56.5) 67 (57.8) 0.220
Diabetes, n (%) 32 (34.8) 25 (22.4) 0.020
Dyslipidemia, n (%) 39 (42.4) 56 (46.6) 0.790
Ejection fraction ≤40% (%) 37 (40.2) 42 (36.2) 0.630
Von Willebrand factor (%) 240.5 (91–755) 191 (76–854) 0.010
CRP (mg/L) 23.2 (4.6–437.0) 20.3 (1.5–422.0) 0.563
IL-1 (pg/mL) 32.0 (7.2–623.1) 31.0 (7.8–102.1) 0.720
IL-6 (pg/mL) 256.1 (34.1–3541.7) 186.7 (1.6–5147.7) 0.0001
IL-12 (pg/mL) 64.3 (23.4–1849.4) 76.7 (21.6–656.8) 0.229
TNF- (pg/mL) 493.6 (220.3–12087.7) 452.4 (219.8–1536.9) 0.184
IFN- (pg/mL) 661.4 (186.5–2219.7) 552.2 (136.6–1043.7) 0.007
IP-10 (pg/mL) 4156 (344–55603) 2892 (249–32254) 0.0001
IL-1ra (pg/mL) 922.9 (227–82463) 968.9 (185–126849) 0.580
IL-4 (pg/mL) 66.4 (30.4–163.2) 75.2 (34.0–144.2) 0.009
IL-10 (pg/mL) 26.1 (3.3–364.8) 38.0 (6.5–745.2) 0.024
MCP-1 (pg/mL) 657.9 (186.2–5976.9) 624.2 (155.7–31305.4) 0.895
MIP-1 (pg/mL) 78.6 (28.7–729.3) 89.5 (20.0–1793.6) 0.511
MIP-1 (pg/mL) 1098.1 (273–19984) 1164.9 (282–14782) 0.725
IL-8 (pg/mL) 259.6 (44.5–42021) 281.9 (27.4–16940.6) 0.240
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ata are expressed as % or as median and range.
atients with RPR and patients without RPR was found
Table 1).
At the logistic regression analysis, pro-inflammatory (IL-
, IP-10 and IFN-) and anti-inflammatory cytokines (IL-
and IL-10) were significantly associated with RPR after
djustment for age, sex, cardiovascular risk factors, ejection
raction, BMI, CRP and vWF (Table 2).
.4. Residual platelet reactivity (RPR) by AA and
yto-chemokine balance profile
Patients with two or three pro-inflammatory cytokines (IP-
0, IL-6, IFN-) in the higher tertile of their distribution
ere significantly more likely to have RPR (OR = 1.95, 95%
.10–3.44 CI, p = 0.04) than patients in the other tertiles, after
djusting for all covariates.
Patients with 1–2 anti-inflammatory cytokines (IL-4 and
L-10) in the higher tertile had significantly decreased risk of
able 2
dds ratio for having RPR by AA in relation to cyto-chemokine levels
multivariate logistic regression analysis)
Odds ratioa 95% CI p value
n(IL-6) 1.80 1.09–2.98 0.022
n(IP-10) 2.31 1.42–3.76 0.001
n(IFN-) 34.8 4.34–278.4 0.001
n(IL-4) 0.014 0.007–0.27 0.004
n(IL-10) 0.55 0.36–0.84 0.006
a Adjusted for adjustment for age, sex, cardiovascular risk factors, ejection
raction, BMI, CRP and vWF.
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p718.5 (2.0–7191.5) 0.335
aving RPR (OR = 0.40, 95% CI 0.22–0.72, p = 0.002) than
atients in the other tertiles after adjusting for all covari-
tes.
Patients with pro-inflammatory cytokines not com-
ensated by the anti-inflammatory cytokines, i.e. pro-
nflammatory cytokines in the third tertile and anti-
nflammatory cytokines in the first and second tertiles (group
) had significantly higher risk of having RPR (OR = 3.85,
5% CI 1.52–9.74, p = 0.004) with respect to patients
ith balanced anti-/pro-inflammatory cytokines (group 1),
.e. pro-inflammatory anti-inflammatory and cytokines in
he same tertiles, whereas patients with anti-inflammatory
esponse overwhelming the pro-inflammatory cytokines
group 3), i.e. pro-inflammatory cytokines in the first or
econd tertiles and anti-inflammatory cytokines in the third
ertile, had lower, but not significant, risk of RPR by AA
OR = 0.55, 95% CI 0.28–1.06, p = 0.073) (Fig. 1).
.5. Relationship between ADP-induced platelet
ggregation and cyto-chemokine levels
The evaluation of the association between pro, anti-
nflammatory markers and platelet aggregation by 2 and
0M ADP, performed by Pearson’s correlation test showed
hat IP-10 and IL-6 serum levels, but not other pro-
nflammatory cytokines (IFN-; IL-1, IL-8, IL-12, TNF-,
CP-1, MIP-1, MIP-1, and VEGF) were mildly but sig-
ificantly related with 2M ADP platelet aggregation (IP-10:
= 0.32, p < 0.001; IL-6: r = 0.28, p < 0.05) and 10M ADP
latelet aggregation (IP-10: r = 0.39, p < 0.001; IL-6: r = 0.29,
< 0.01).
A.M. Gori et al. / Atheroscleros
Fig. 1. Odds ratio for having residual platelet reactivity (RPR) by 1 mM AA
or 10M ADP according to the pro-inflammatory and anti-inflammatory
balance: group 1: balanced pro-/anti-inflammatory cytokines; group 2: pro-
inflammatory cytokines not compensated by anti-inflammatory cytokines;
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Droup 3: anti-inflammatory response overwhelming the pro-inflammatory
esponse.
Anti-inflammatory cytokines IL-4 and IL-10 serum levels
ere inversely related with 2M ADP platelet aggregation
IL-4: r = −0.26, p < 0.05; IL-10: r = −0.26, p < 0.05) and
ith 10M ADP-PA platelet aggregation (IL-4: r = −0.27,
< 0.05; IL-10: r = −0.28, p < 0.05).
.6. Relationship between CRP, vWF levels and
DP-induced platelet aggregationNo significant association between CRP serum levels and
DP-induced platelet aggregation was found.
1
m
able 3
linical and laboratory characteristics according to the presence or the absence of
70%)
With RPR (n = 68)
ge (year) 68.3 (65.7–70.8)
ex (M/F) 45/23
moking habit (%) 25 (36.8)
ypertension (%) 45 (66.2)
iabetes (%) 20 (29.4)
yslipidemia (%) 28 (41.2)
jection fraction ≤40% (%) 41 (60.3)
on Willebrand factor (%) 232.5 (76.0–854.0)
RP (mg/L) 23.2 (4.6–437.0)
L-1 (pg/mL) 35.4 (7.4–96.1)
L-6 (pg/mL) 256.6 (1.6–3541.7)
L-12 (pg/mL) 60.3 (21.6–1849.4)
NF- (pg/mL) 499.7 (219.8–1490.9)
FN- (pg/mL) 667.2 (277.0–1345.5)
P-10 (pg/mL) 4957.3 (610–55603)
L-1ra (pg/mL) 987.8 (186–15476)
L-4 (pg/mL) 67.5 (30.4–102.2)
L-10 (pg/mL) 26.4 (5.1–263.9)
CP-1 (pg/mL) 618.1 (186.2–5976.9)
IP-1 (pg/mL) 89.2 (19.9–1793)
IP-1 (pg/mL) 1172.8 (343.0–8596)
L-8 (pg/mL) 237.4 (54.6–21373.2)
EGF (pg/mL) 720.5 (2.0–3142.5)
ata are expressed as % or as median and range.is 202 (2009) 255–262 259
A significant association between vWF levels and platelet
ggregation by 2M ADP (r = 0.21, p < 0.05) and 10M
DP platelet aggregation (r = 0.22, p < 0.05) was docu-
ented.
.7. Residual platelet reactivity (RPR) by ADP and
yto-chemokine, CRP and vWF levels
Sixty-eight patients of 208 (32.7%) had RPR (ADP-
nduced platelet aggregation ≥70%) by 10M ADP and 16
f 208 (7.6%) patients by 2M ADP. As the 16 patients found
ith RPR by 2M ADP had RPR also by 10M ADP, we
eport below the results obtained with 10M ADP.
In addition to diabetes and vWF also IL-6, IP-10 and
FN- serum levels significantly differed according to RPR
Table 3). No significant difference in CRP levels between
atients with RPR and patients without RPR was found
Table 3).
At the multiple logistic regression analysis, after adjust-
ent for all potential confounders, in addition to diabetes,
lso IL-4, IFN-, IP-10 but not IL-6 levels remained signif-
cant and independent predictors of RPR detected by 10M
DP (Table 4).
.8. Residual platelet reactivity (RPR) by ADP and
yto-chemokine balance profilePatients with two or three pro-inflammatory cytokines (IP-
0, IL-6 and IFN-) in the highest tertile were significantly
ore likely to have RPR (OR = 2.49, 95% CI 1.33–4.68,
residual platelet reactivity by 10M ADP-PA (ADP-platelet aggregation
Without RPR (n = 140) p
68.3 (66.9–69.8) 0.093
107/33 0.219
68 (48.6) 0.307
86 (61.4) 0.977
25 (17.9) 0.047
66 (47.1) 0.602
58 (41.4) 0.006
221 (82.0–835.0) 0.036
21.5 (1.5–422.0) 0.743
29.1 (7.2–623.1) 0.335
188.9 (34.1–5147.7) 0.003
76.7 (24.8–600.5) 0.234
469.0 (259.5–12087.7) 0.515
568.6 (136.6–2219.7) 0.015
3238.3 (249–43005) 0.0001
929.5 (185–126849) 0.528
72.5 (30.4–163.2) 0.123
37.8 (3.3–745.2) 0.063
649.6 (155.7–31305.4) 0.998
72.9 (28.7–729.3) 0.317
1142.5 (273.0–19984) 0.281
295.2 (27.4–42021) 0.234
738.2 (2.7–7191.5) 0.605
260 A.M. Gori et al. / Atheroscleros
Table 4
Odds ratio for having RPR by 10M ADP in relation to cyto-chemokine
levels (multivariate logistic regression analysis)
Odds ratioa 95% CI p value
Ln(IP-10) 2.51 1.70–3.72 0.001
Ln(IFN-) 2.51 1.70–3.72 0.001
Ln(IL-4) 0.07 0.017–0.295 0.001
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raction, BMI, CRP and vWF.
= 0.005) than patients in the other tertiles, after adjustment
or all covariates.
Patients with 1–2 anti-inflammatory cytokines (IL-4 and
L-10) in the higher tertile had significantly decreased risk of
aving RPR (OR = 0.47, 95% CI 0.26–0.87, p = 0.015) than
atients in the other tertiles after adjustment for all covari-
tes.
Patients with pro-inflammatory cytokines not com-
ensated by the anti-inflammatory cytokines, i.e. pro-
nflammatory cytokines in the third tertile and anti-
nflammatory cytokines in the first and second tertiles
group 2) had significantly higher risk of having RPR
OR = 2.33, 95% CI 1.01–5.95, p = 0.048) with respect to
atients with balanced anti-/pro-inflammatory cytokines, i.e.
ro-inflammatory anti-inflammatory and cytokines in the
ame tertiles (group 1). Patients with anti-inflammatory
esponse overwhelming the pro-inflammatory response, i.e.
ro-inflammatory cytokines in the first or second tertiles
nd anti-inflammatory cytokines in the third tertile (group
) had significantly lower risk of RPR (OR = 0.37, 95% CI
.18–0.74, p = 0.005) (Fig. 1).
. Discussion
This study provides new insights into the association
etween inflammation and residual platelet reactivity on
ntiplatelet treatment, which was previously found to be
elated to the occurrence of clinical events in high-risk
atients such as ACS patients undergone PCI on dual
ntiplatelet agents [9,15,16].
In the present study, by using extensive array of
ytokines and other inflammatory markers, we demonstrated
modulatory effect of the interplay between pro- and anti-
nflammatory molecules on platelet function in patients with
marked endothelial, leukocyte and platelet activation, such
s those with ACS undergone PCI.
Several cytokines are involved in the inflammatory pro-
esses, have overlapping, antagonistic, and synergic effects
n many cell types and up-regulate and down-regulate the
roduction of other cytokines and inflammatory mediators
23,24]. For these reasons, it is crucial to evaluate a full pro-
le of Th1 and Th2 pro-inflammatory and anti-inflammatory
ytokines to obtain a more complete and precise picture of
volving interaction between platelets and leukocytes.
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The acute coronary syndromes are characterized by
n acute inflammatory response in which high levels
f pro-inflammatory markers [25–27] and low levels of
he anti-inflammatory cytokine IL-10 were documented
28,29].
Inflammatory mediators are able to activate different cell
ypes such as monocytes and polymorphonuclear cells, and
o induce the production of prothrombotic and chemotactic
actors by these cells [25], which in their turn, determine
he activation of platelets. Upon activation, platelets are able
o bind to leukocytes and endothelial cells and promote
he release of prothrombotic and pro-inflammatory factors,
eading to a subsequent leukocyte attachment to injured
ndothelium [5,30].
On the other hand, activated platelets have been implicated
ot only in thrombosis, but also in inflammatory reactions
nd immune response; several studies have demonstrated the
apability of activated platelets to induce an inflammatory
eaction in cells of the vascular wall, leading to a subse-
uent cellular activation and production of prothrombotic and
hemotactic factors [31].
A link between the hemostatic and the inflammatory sys-
em is represented by vWF, which provides an adhesive
omponent for PMNs and monocytes [32].
Present findings of the relationship between inflammation
nd platelet aggregation are in keeping with clinical studies
howing the high prevalence of RPR in the acute phase of
he disease [15,16] and with the observation that in the ACS
atients the leukocyte count and ESR are associated with an
ncreased risk of having RPR despite dual antiplatelet therapy
9].
In this study we have documented a significant role of IP-
0 in influencing platelet reactivity. IP-10 is a chemoattractant
rotein which promotes T cell adhesion to endothelial cells
nd it is a peculiar characteristic of human Th1 response [33].
therosclerosis may be considered mainly a Th1-driven dis-
ase. Furthermore, in vitro studies demonstrated that Th1
ells are able to induce the synthesis of monocyte tissue
actor, which may determine the thrombin formation and
ubsequent platelet activation [34].
In our study we have documented an inverse relation-
hip between anti-inflammatory cytokines (IL-10 and IL-4)
evels and RPR. IL-10 has multifaced anti-inflammatory
roperties, including inhibition of the prototypic inflam-
atory transcription factor nuclear factor kappa B and
romotion of phenotypic switch of lymphocytes into Th2
henotype [35]. Moreover, clinical studies demonstrated
hat elevated IL-10 levels are predictive of a better clini-
al outcome after acute coronary syndromes, and abrogate
he increased risk associated with elevated CRP levels
28,29].
We have found no association between platelet reactivity
nd the cyto-chemokines IL-1, IL-1ra, IL-8, IL-12, MCP-
, MIP-1, TNF-, and VEGF. This finding may stem from
he different half lives of the cyto-chemokines measured and
rom the intricate feedback among cytokines.
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[
[
[
[A.M. Gori et al. / Athero
.1. Study limitations
Our study has some limitations. First, our study is a cross-
ectional study, therefore, we are not able to demonstrate a
ausal relationship between inflammatory state and platelet
eactivity. Second, we investigated the serum levels of cyto-
hemokines, but the actual interaction platelets/leukocytes
ould have been obtained by the measurement of circulat-
ng platelet monocyte-aggregates and would have provided a
urther insight into the mechanisms involved in the different
esponse to antiplatelet drugs [36]. Third, in this study we do
ot provide data about the relation between RPR and adverse
schemic events.
The possible modulation of the anti-inflammatory effects
f ACE inhibitors and statins may have influenced the inflam-
atory state of our patients, nevertheless the large use of these
rugs in our study group does not allow us to explore the inter-
ction among platelet activation, inflammatory state, and the
bove-mentioned drugs.
In conclusion, our study documented that a pro-
nflammatory state, not counteracted by an anti-inflammatory
esponse, influences platelet hyper-reactivity in ACS patients
n dual antiplatelet treatment. Present findings suggest that
urther studies, looking at the platelet activation during the
cute phase of disease, have to consider that any intervention
ddressed to reduce inflammatory burden may also influence
latelet activation.
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